MA38935B1 - Dérivés de diazacarbazole à titre de ligands tau-pet - Google Patents
Dérivés de diazacarbazole à titre de ligands tau-petInfo
- Publication number
- MA38935B1 MA38935B1 MA38935A MA38935A MA38935B1 MA 38935 B1 MA38935 B1 MA 38935B1 MA 38935 A MA38935 A MA 38935A MA 38935 A MA38935 A MA 38935A MA 38935 B1 MA38935 B1 MA 38935B1
- Authority
- MA
- Morocco
- Prior art keywords
- fluoro
- aggregates
- dipyrido
- pyridin
- pyrrole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Cette invention concerne un composé de formule générale (i) dans laquelle r est un atome d'hydrogène ou de tritium ; f est un fluoro ou 18fluoro ; ou un sel d'addition d'acide pharmaceutiquement acceptable de celui-ci. Les composés de formule i comprennent le 2-(6-fluoro-pyridin-3-yl)-9h-dipyrido[2,3-b; 3',4'-d]pyrrole, le 3h-2-(6-fluoro-pyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole et le [18f]-2-(6-fluoro-pyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole. Ils peuvent être utilisés pour lier et soumettre à imagerie les agrégats tau et les agrégats de feuillets bêta associés comprenant, entre autres, les agrégats bêta-amyloïdes ou les agrégats d'alpha-synucléine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13187764 | 2013-10-08 | ||
PCT/EP2014/071283 WO2015052105A1 (fr) | 2013-10-08 | 2014-10-06 | Dérivés de diazacarbazole à titre de ligands tau-pet |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38935A1 MA38935A1 (fr) | 2016-04-29 |
MA38935B1 true MA38935B1 (fr) | 2016-12-30 |
Family
ID=49301396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38935A MA38935B1 (fr) | 2013-10-08 | 2016-03-25 | Dérivés de diazacarbazole à titre de ligands tau-pet |
Country Status (33)
Country | Link |
---|---|
US (2) | US10004817B2 (fr) |
EP (1) | EP3055308B1 (fr) |
JP (1) | JP6194416B2 (fr) |
KR (1) | KR101770531B1 (fr) |
CN (1) | CN105358558B (fr) |
AR (1) | AR097931A1 (fr) |
AU (1) | AU2014333996B2 (fr) |
CA (1) | CA2917191C (fr) |
CL (1) | CL2016000728A1 (fr) |
CR (1) | CR20150663A (fr) |
DK (1) | DK3055308T3 (fr) |
EA (1) | EA028483B1 (fr) |
ES (1) | ES2657121T3 (fr) |
HK (1) | HK1215574A1 (fr) |
HR (1) | HRP20180049T1 (fr) |
HU (1) | HUE035413T2 (fr) |
IL (1) | IL243249A0 (fr) |
LT (1) | LT3055308T (fr) |
MA (1) | MA38935B1 (fr) |
MX (1) | MX2016002234A (fr) |
MY (1) | MY190196A (fr) |
NO (1) | NO3055308T3 (fr) |
PE (1) | PE20160159A1 (fr) |
PH (1) | PH12016500249B1 (fr) |
PL (1) | PL3055308T3 (fr) |
PT (1) | PT3055308T (fr) |
RS (1) | RS56777B1 (fr) |
SG (1) | SG11201602786UA (fr) |
SI (1) | SI3055308T1 (fr) |
TW (1) | TWI513698B (fr) |
UA (1) | UA116164C2 (fr) |
WO (1) | WO2015052105A1 (fr) |
ZA (1) | ZA201509013B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2247558T1 (sl) | 2008-02-14 | 2022-07-29 | Eli Lilly And Company | Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij |
LT3055308T (lt) | 2013-10-08 | 2018-02-12 | F. Hoffmann-La Roche Ag | Diazakarbazolo dariniai kaip taupet ligandai |
CN106459059B (zh) | 2014-05-13 | 2019-09-24 | 豪夫迈·罗氏有限公司 | 氘化杂环化合物和其作为成像剂的用途 |
KR102621513B1 (ko) * | 2015-02-02 | 2024-01-04 | 유씨비 바이오파마 에스알엘 | 9h-피롤로-디피리딘 유도체 |
US20180264146A1 (en) | 2015-07-15 | 2018-09-20 | Ac Immune S.A. | Novel imaging compounds |
EP3118202A1 (fr) | 2015-07-15 | 2017-01-18 | AC Immune S.A. | Dérivés de dihydropyridopyrrole en tant que ligands tau-pet |
JP7059270B2 (ja) * | 2016-07-22 | 2022-04-25 | エーシー・イミューン・エス・アー | タウタンパク質凝集体を画像化するための化合物 |
MX2018016279A (es) | 2016-07-22 | 2019-09-06 | Ac Immune Sa | Compuestos para formacion de imagenes de agregados de proteinas tau. |
WO2018024642A1 (fr) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | Dérivés de 9h-pyrrolo-dipyridine |
WO2018024643A1 (fr) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | Dérivés de 9h-pyrrolo-dipyridine |
CN109689653B (zh) * | 2016-09-09 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 用于制备2-(6-硝基吡啶-3-基)-9H-二吡啶并[2,3-b;3’,4’-d]吡咯的方法 |
EA202091767A1 (ru) * | 2018-01-24 | 2021-02-16 | Ац Иммуне Са | Новый способ получения визуализирующего соединения |
WO2019145293A1 (fr) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Compositions diagnostiques pour l'imagerie tep, procédé de fabrication de la composition diagnostique, et utilisation de celle-ci dans des diagnostics |
EP3743426A1 (fr) | 2018-01-24 | 2020-12-02 | AC Immune SA | Composés d'azacarboline pour la détection d'agrégats de tau |
WO2019145291A1 (fr) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Composés gamma-carboline pour la détection d'agrégats de tau |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2247558T1 (sl) * | 2008-02-14 | 2022-07-29 | Eli Lilly And Company | Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij |
US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
CN102119162B (zh) | 2008-06-11 | 2014-10-08 | 健泰科生物技术公司 | 二氮杂咔唑及其使用方法 |
WO2010011964A2 (fr) | 2008-07-24 | 2010-01-28 | Siemens Medical Solutions Usa, Inc. | Agents d'imagerie utiles pour identifier une pathologie |
US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
KR101316982B1 (ko) * | 2009-03-23 | 2013-10-15 | 일라이 릴리 앤드 캄파니 | 신경계 장애를 검출하기 위한 조영제 |
US20110183938A1 (en) * | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
US20150368244A1 (en) * | 2011-01-31 | 2015-12-24 | Genentech, Inc. | Diazacarbazoles and methods of use |
LT3055308T (lt) * | 2013-10-08 | 2018-02-12 | F. Hoffmann-La Roche Ag | Diazakarbazolo dariniai kaip taupet ligandai |
-
2014
- 2014-10-06 LT LTEP14781169.9T patent/LT3055308T/lt unknown
- 2014-10-06 EA EA201690515A patent/EA028483B1/ru not_active IP Right Cessation
- 2014-10-06 PT PT147811699T patent/PT3055308T/pt unknown
- 2014-10-06 NO NO14781169A patent/NO3055308T3/no unknown
- 2014-10-06 HU HUE14781169A patent/HUE035413T2/en unknown
- 2014-10-06 ES ES14781169.9T patent/ES2657121T3/es active Active
- 2014-10-06 PL PL14781169T patent/PL3055308T3/pl unknown
- 2014-10-06 WO PCT/EP2014/071283 patent/WO2015052105A1/fr active Application Filing
- 2014-10-06 CA CA2917191A patent/CA2917191C/fr active Active
- 2014-10-06 SI SI201430549T patent/SI3055308T1/en unknown
- 2014-10-06 AU AU2014333996A patent/AU2014333996B2/en active Active
- 2014-10-06 MX MX2016002234A patent/MX2016002234A/es active IP Right Grant
- 2014-10-06 UA UAA201604290A patent/UA116164C2/uk unknown
- 2014-10-06 EP EP14781169.9A patent/EP3055308B1/fr active Active
- 2014-10-06 SG SG11201602786UA patent/SG11201602786UA/en unknown
- 2014-10-06 PE PE2015002706A patent/PE20160159A1/es active IP Right Grant
- 2014-10-06 TW TW103134795A patent/TWI513698B/zh active
- 2014-10-06 RS RS20180058A patent/RS56777B1/sr unknown
- 2014-10-06 JP JP2016515518A patent/JP6194416B2/ja active Active
- 2014-10-06 CN CN201480037389.5A patent/CN105358558B/zh active Active
- 2014-10-06 MY MYPI2016000604A patent/MY190196A/en unknown
- 2014-10-06 DK DK14781169.9T patent/DK3055308T3/en active
- 2014-10-06 AR ARP140103712A patent/AR097931A1/es active IP Right Grant
- 2014-10-06 KR KR1020167008013A patent/KR101770531B1/ko active IP Right Grant
-
2015
- 2015-12-10 ZA ZA2015/09013A patent/ZA201509013B/en unknown
- 2015-12-15 CR CR20150663A patent/CR20150663A/es unknown
- 2015-12-21 IL IL243249A patent/IL243249A0/en active IP Right Grant
-
2016
- 2016-02-04 PH PH12016500249A patent/PH12016500249B1/en unknown
- 2016-03-24 HK HK16103514.3A patent/HK1215574A1/zh unknown
- 2016-03-25 MA MA38935A patent/MA38935B1/fr unknown
- 2016-03-30 CL CL2016000728A patent/CL2016000728A1/es unknown
- 2016-04-07 US US15/093,366 patent/US10004817B2/en active Active
-
2018
- 2018-01-10 HR HRP20180049TT patent/HRP20180049T1/hr unknown
- 2018-05-15 US US15/980,080 patent/US11058781B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38935B1 (fr) | Dérivés de diazacarbazole à titre de ligands tau-pet | |
EA202090255A2 (ru) | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов | |
MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
FR2926554B1 (fr) | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique | |
MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
MA38647B1 (fr) | Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x | |
MA34450B1 (fr) | Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique | |
MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
MA38385A1 (fr) | Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) | |
AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
MA38645A1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
MA34098B1 (fr) | Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs | |
PH12020551713A1 (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators | |
MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
FR3020809B1 (fr) | Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique | |
MA37849A1 (fr) | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux | |
RU2013110377A (ru) | Новые производные 6,7-двузамещенного изохинолина и их применение | |
MA35878B1 (fr) | Utilisation thérapeutique de dérivés d'imidazopyridine | |
MA39054A1 (fr) | Dérivés pyridyle bicycliques à anneaux fusionnés utilisés en tant qu'inhibiteurs de fgfr4 | |
MA35155B1 (fr) | Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline | |
EA201301204A1 (ru) | Алициклические производные n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов и лекарственные средства на их основе |